What they say:
A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Vitamin-based therapy for pulmonary arterial hypertension: Cholecalciferol (a form of Vitamin-D) inhibits the development of pulmonary arterial hypertension via down regulation of Notch3 and its target gene Hes-5
Significance of the study:
Cholecalciferol, by increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thus, pharmacological formulations encompassing “Cholecalciferol or its analog, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension.
Details of the research findings:
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How Cholecalciferol inhibits Notch-3 expression
For purchase and payment details, you may reach us at firstname.lastname@example.org
# Research cooperation
Citation: Boominathan, L., Vitamin-based therapy for pulmonary arterial hypertension: Cholecalciferol (a form of Vitamin-D) inhibits the development of pulmonary arterial hypertension via down regulation of Notch3 and its target gene Hes-5, 22/May/2017, 9.53 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at email@example.com